Sanne W C M Janssen

Sanne W C M Janssen

Auto-generated profile, based on publicly available information

Sanne W C M Janssen

Department of Pediatrics, Division of Pediatric Infectious Diseases and Immunology, Erasmus MC-Sophia Children's Hospital, University Medical Center, Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2025 in eClinicalMedicine
Verified
Journal Article
Open access
BWBo M. van der Weijden
Bo M. van der Weijden
SJSanne W.C.M. Janssen
Sanne W.C.M. Janssen
MWMarijke C. van der Weide
Marijke C. van der Weide
RVRenske J.P.M. Cornelisse-Van Vugt
Renske J.P.M. Cornelisse-Van Vugt
GTGavin William Ten Tusscher
Gavin William Ten Tusscher
NANiek B Achten
Niek B Achten
Newborns are at risk for early-onset sepsis (EOS), occurring 0.2–2.0 per 1000 live births, and for antibiotic overtreatment: approximately 5–15% receive antibiotics for suspected EOS under conventional guidelines with categorical risk factor assessment. Use of the multivariate neonatal EOS calculator prediction tool can reduce overtreatment, but no trials have been conducted to compare its safety to these categorical guidelines. Between April 12th, 2022, and March 19th, 2024, we conducted an open-label, two-armed, cluster-randomised controlled trial among newborns born at ≥34 weeks’ gestational age with ≥1 EOS risk factor, comparing 10 hospitals randomised 1:1 to EOS calculator use versus categorical guideline use (ClinicalTrials.gov number: NCT05274776). The EOS calculator was slightly adapted for Dutch use. The co-primary non-inferiority outcome assessed safety using four predefined harm criteria (respiratory support, circulatory support, referral to intensive care unit, and culture-confirmed EOS). Non-inferiority was established if the upper limit of the 95% confidence interval (CI) for the relative risk did not exceed 1.5. The co-primary superiority outcome assessed the reduction of participants starting antibiotic therapy for suspected EOS within 24 h postpartum. Secondary endpoints were the duration of antibiotic therapy and the initiation of antibiotic therapy between 24 and 72 h after birth. Intention-to-treat and per-protocol analyses were performed. 1830 newborns (183 per cluster) were included. At least one harm criterion was present in 64 (7.0%) of 915 in the EOS calculator arm and 134 (14.6%) of 915 in the categorical guideline arm (relative risk 0.48; 95% Cl 0.36–0.63). Antibiotics for suspected EOS were started in 66 (7.2%) of 915 in the EOS calculator arm, compared with 243 (26.6%) of 915 in the categorical guideline arm (absolute risk reduction: 19.0%, 95% CI 11.3–26.7). Median duration of antibiotics was longer in the EOS calculator arm (5.5 days, IQR 1.8–6.6) than in the categorical guideline arm (2.1 days, IQR 1.6–6.3) (P 0.0019). We found no difference in the proportion of newborns started on antibiotic therapy for suspected EOS between 24 and 72 h after birth. Adverse event rates were similar between arms. Readmission for suspected early-onset sepsis occurred three times in the EOS calculator and two times in the categorical guideline arm. Any cultures obtained at readmission remained negative, and any symptoms resolved completely. These trial data support safety and effectiveness of the EOS calculator for harm criteria and for the proportion of participants that started antibiotic therapy. This study was supported by SPIN, the General Paediatrics Research Network of the Dutch Association for Paediatrics, supported by het Cultuurfonds.

9 March 2026 in JMIR Medical Informatics
Verified
Journal Article
Open access
SVSanne E W Vrijlandt
Sanne E W Vrijlandt
SJSanne W C M Janssen
Sanne W C M Janssen
ARAnnemarie M.C. van Rossum
Annemarie M.C. van Rossum
NANiek B Achten
Niek B Achten
OOOostenbrink Oostenbrink
Oostenbrink Oostenbrink
Clinical decision-making is a critical process where physicians balance risks and benefits. Clinical Decision Support Systems (CDSSs) are increasingly used to help in this process. The regulatory landscape for CDSSs is evolving significantly, with the new European Medical Device Regulation (MDR) now requiring, CE certification for certain CDSSs. This shift poses challenges for health care providers to develop CDSSs in an effective and useful manner while adhering to regulations. This viewpoint comments on diverse challenges and provides solutions to develop a reliable, well integrated and practical tool for clinical use. Using three tools (the Early Onset Sepsis Calculator, Feverkidstool, and Neonatal Procalcitonin Intervention Study algorithm) as examples, we explore the development of CDSSs across four core characteristics: scientific basis, technical aspects, safety, and sustainability. These characteristics recur across the main development processes; scientific development, regulatory assessment, and implementation in routine practice. Successful integration of CDSSs into clinical practice requires a comprehensive understanding of the interconnections between these processes. For example, decisions on algorithm validation and platform selection in the scientific process influence choices for technical safety during the regulatory process. Developers should consider both regulation requirements and clinical needs, to create CDSSs that are not only compliant but also adaptable to the rapidly changing healthcare landscape. We outline a developer’s checklist, for practical guidance, but also appeal for structural support, including national protocols and dedicated hospital roles, to help developers implement CDSSs successfully.